PharmID was founded in early 2017 to develop and commercialize technology developed by MarqMetrix for healthcare and pharmacy uses. MarqMetrix has been providing non-destructive quantitative and qualitative Raman Spectroscopy tools and services to industrial clients (petro- and agri-chemical, pharmaceutical and others) for the last 5+ years. Two of the founders of PharmID have family connections in pharmacy, so it was only a matter of time before the connection of Raman Spectroscopy to assist pharmacy in identification and verification of medications was made. PharmID is currently pursuing products to support drug diversion prevention, IV compounding verification and other activities where knowing for certain what-the-drug-is is important.

PharmID was founded in early 2017 to develop and commercialize technology developed by MarqMetrix for healthcare and pharmacy uses. MarqMetrix has been providing non-destructive quantitative and qualitative Raman Spectroscopy tools and services to industrial clients (petro- and agri-chemical, pharmaceutical and others) for the last 5+ years. Two of the founders of PharmID have family connections in pharmacy, so it was only a matter of time before the connection of Raman Spectroscopy to assist pharmacy in identification and verification of medications was made. PharmID is currently pursuing products to support drug diversion prevention, IV compounding verification and other activities where knowing for certain what-the-drug-is is important.

23andMe has more than 12 million customers worldwide. Our Health + Ancestry Service allows individuals to acquire this information from the privacy of their own homes, without medical requisition. Nearly 30% of consumers who undergo direct-to-consumer (DTC) genetic testing choose to share their reports with healthcare providers to inform conversations about their health.1,2,3 Our Healthcare Professionals community was created to help U.S. providers and their patients navigate genetics together in order to make important informed decisions about prevention, treatment and healthy living.

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy, and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense, was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.